LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.66 USD | +0.68% |
|
-0.84% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.66
USD
Average target price
35.6
USD
Spread / Average Target
+101.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 451M | |
| +15.58% | 121B | |
| +16.60% | 110B | |
| +17.73% | 25.93B | |
| -24.33% | 19.27B | |
| -19.35% | 16.01B | |
| -17.95% | 15.66B | |
| -48.32% | 14.89B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target
